Amylyx announces positive topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia

Amylyx Pharmaceuticals, Inc.

Positive topline results announced Aug 18, 2026 from LUCIDITY Phase 3 trial of avexitide in post-bariatric hypoglycemia (PBH).
Trial enrolled participants with PBH following Roux-en-Y gastric bypass surgery; no efficacy numbers disclosed in filing text.
Investor conference call and slide deck (Exhibit 99.1) held same day; detailed endpoint data not included in available excerpt.
Avexitide is Amylyx's (AMLX) candidate for PBH; positive readout could support registration pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.